Celecoxib

Celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.

Product Specifications

CAS Number

[169590-42-5]

Product Name Alternative

SC 58635

UNSPSC

12352005

Hazard Statement

H360, H373, H410

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Celecoxib.html

Purity

99.89

Solubility

DMSO : ≥ 50 mg/mL

Smiles

CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O

Molecular Formula

C17H14F3N3O2S

Molecular Weight

381.37

Precautions

H360, H373, H410

References & Citations

[1]Penning TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib) . J Med Chem. 1997|[2]Liu DB, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin. 2012 May;33 (5) :682-90.|[3]Suri A, et al. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. Oncotarget. 2016 Apr 8.|[4]Hou XL, et al. Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone. Neural Regen Res. 2015 Nov;10 (11) :1836-40.|[5]Liu C, et al. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. Sci Rep. 2018 Mar 7;8 (1) :4108.|[6]Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10 (8) :3622-3635.